Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.
The president and CEO of the Nova Scotia Health Authority is promising to cut the number of Nova Scotians waiting for surgery by 10,000 between now and mid-2025, just in time for the next provincial election.